FDA, weight loss and diabetes drugs

Yearslong shortage of popular weight-loss and diabetes drugs resolved, FDA says
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity treatments improve.
Novo’s Weight Loss Drugs Removed from FDA Shortage List
The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list. The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and diabetes drugs,
Weight-loss drugs aren’t just slimming waists. They’re shifting the economy.
Ozempic, Mounjaro and Wegovy may not be the lightbulb, jet airplane or internet, but their impact is expected to be so significant it could shift GDP.
Weight loss drugs linked to dozens of deaths
The medical director of the NHS has warned of the side effects of weight loss drugs after figures revealed the number of deaths associated with the jabs
Ozempic, Wegovy Linked To Potential Vision Loss
Patients on semaglutide ( Ozempic, Wegovy) had a 32% increased relative risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) compared to people not taking the drug, researchers reported Feb. 20 in JAMA Ophthalmology.
These Drugs Could Offset the Side Effects of Weight Loss
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
FDA announces end to Wegovy and Ozempic drug shortages, but it could mean higher prices
The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is over.
Weight-loss drugs could help extend life of replacement joints, research indicates
Even slight weight loss spurred on by cutting-edge GLP-1 drugs can help prevent replacement knees and hips from wearing out, a new study suggests.
Ozempic and Wegovy shortage ends, setting up weight loss drug showdown
Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared Friday. Why it matters: That's good news for Novo Nordisk (whose stock rose 5% Friday) and potentially bad news for Hims & Hers (which fell 26%).
Patients struggle with lack of consistent coverage for popular weight-loss drugs
Supplies of high-demand obesity treatments are improving, but that doesn’t mean it's easier to get them. Many employers and ...
Are Weight Loss Injections Safe? What to Know Before Starting One
Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...
What to know before considering weight loss jabs, as related deaths rise
Some people may turn to private healthcare providers in order to get their hands on the weight loss jabs. However, Britons ...
No more needles? Startups are testing patches to deliver weight-loss drugs and other medications.
Local companies are developing technologies that they hope could replace a painful poke with something that feels more like ...
In China you can get Ozempic and Wegovy within the hour for just $100 a month
Delivery apps are allowing Chinese citizens to get their hands on the popular weight-loss and diabetes drugs at the touch of a button.
Hims & Hers Stock Plummets. The Wegovy Shortage Is Over.
The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.
Weight-loss drugs are about to get a lot better
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.